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Acute pain after total hip arthroplasty does not predict
the development of chronic postsurgical pain 6 months later
Hance Clarke . Joseph Kay .
Nicholas Mitsakakis . Joel Katz
Abstract
Purpose Much remains unknown about the relationship
between acute postoperative pain and the development of
pathologic chronic postsurgical pain (CPSP). The purpose
of this project was to identify the extent to which maximum
pain scores on movement over the first two days after total
hip arthroplasty predicted the presence of chronic pain
6 months later after controlling for potentially important
covariates.
Methods The sample comprised 82 of 1I4 patients who
pafticipated in a double-blinded randomized controlled
trial in which all patients received acetaminophen I g p.o.,
celecoxib 400 mg p.o., and dexamethasone 8 mg i.v.,
1-2 h preoperatively. In addition, patients received gaba-
pentin (GBP) 600 mg (G2) or placebo (Gl and G3) 2h
prior to surgery [Gl: placebo/placebo (n : 38); G2: GBPI
placebo (rz : 38); G3: placebo/GBP (n : 38)1. In the
PACU, patients received gabapentin 600 mg (G3) or pla-
cebo (G1 and G2). Follow-up data from tbe 82 patients
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who were contacted by telephone 6 months postsurgery
were used for the current study.
Results Maximal movement-evoked pain intensity over
the first two postoperative days (P : 0.38) failed to predict
the presence of CPSP 6 months later after controlling for
age (P: 0.09), treatment group (P : 0.91), and cumula-
tive morphine consumption (P : 0.8) (multivariate logistic
regression likelihood ratio test against the intercept only
model P:0.59).
Conclusion Neither maximum movement-evoked acute
pain, nor any other factor measured, predicted the presence
of CPSP at 6 months. Further research is needed to identify
risk factors for CPSP after total hip arthroplasty.
Keywords Acute pain . Chronic postsurgical pain .
Total hip arthrcplasty
Introduction
Chronic postsurgical pain (CPSP) has been defined as
pathologic pain that persists for longer than 2 months
postsurgery [1]. Neuropathic pain (pain arising as a direct
consequence of a lesion or disease affecting the somato-
sensory system) [2] has been implicated as a major con-
tributor to the development of neuropathic pain [3, 4]. A
prospective longitudinal study examining patients that
experienced intense neuropathic pain in the acute hospital
period found that 56Vo of these patients reported chronic
neuropathic pain I year postdischarge [5].
One year after total hip arthroplasty, the incidence of
CPSP has been reported to be as high as 3OVo 16l. Results
from a Danish nationwide study found that l2.l7o of
patients after hip arthroplasty were significantly impaired
(12-18 months later) in their daily activities by CPSP [7].
After most surgical procedures, the majority of patients
recover uneventfully. It is evident that some surgical pro-
cedures are associated with a higher incidence of CPSP [6].
CPSP is becoming a widely recognized societal and eco-
nomic problem. Currently, up to 25Vo of all patients referred
to chronic pain treatment centres suffer with CPSP [8].
The risk factors associated with the development of CPSP
are currently under investigation [4]. The most consistent
finding in the literature thus far has been that the presence of
current pain (either preoperative or acute postsurgical pain)
predicts future pain [4,9-12]. Other factors such as younger
age [3, 14], female gender [9, 15], the presence of anxiety
[9, 16], pain catastrophizing [17], and other psychological
variables such as emotional numbing [18] have been shown
to predict the development ofpostsurgical pain after a variety
of surgical procedures [4]. We must continue efforts to
determine which aspects of the perioperative pain experi-
ence are predictive of the transition to pain chronicity:
qualities specific to the pain itself (e.g. intensity, quality,
duration), or qualities inherent to the individuals that are
reporting the pain (e.g. response bias, psychological vul-
nerability, genetic predisposition) [ ] ?
In previous work, we found that regardless of the timing
and whether or not gabapentin (an a26 voltage-dependent
calcium channel blocker) was administered (i.e. before
surgery/after surgery/or not at all), differences were not
found in the acute perioperative period with respect to
opioid consumption, pain at rest, or movement-evoked pain
after total hip arthroplasty [19]. All patients also received a
clinically relevant, preventive, multimodal regimen of
acetaminophen, celecoxib (Cox-2 selective inhibitor), and
spinal anesthesia [9]. The aim of the current paper was to
test whether maximal movement-evoked acute pain scores
would predict the development of CPSP in the sample of
patients who had undergone total hip arthroplasty.
Several trials have demonstrated that the intensity of
acute postoperative pain predicts the transition to CPSP|1, 20-221. In the present paper, we selected maximal
movement pain as the primary pain outcome measure
because movement pain scores are typically higher than
pain scores at rest. As well, movement-evoked pain is more
difficult to treat than rest pain [23], and it is an important
marker of postoperative physical activity such as the ability
to bear weight during ambulation [24]. Secondary outcome
measures included preoperative anxiety, morphine con-
sumption, age and gender, and their relationship to the
development of CPSP.
Materials and methods
This study was approved by the Sunnybrook Health Sci-
ences Centre Research Ethics Board. All patients save
informed, written consent to participate. Eligible patients
were between the ages of 18 and 75 years, had an ASA
physical status score of I, II, or III, and had undergone total
hip arthroplasty. Patients were not eligible if they met any
of the following exclusion criteria: a known allergy to any
of the medications being used; a history of drug or alcohol
abuse; a history of being on chronic pain medications (.e.
slow-release preparations of opioids); rheumatoid arthritis;
a psychiatric disorder; a history of diabetes with impaired
renal function; a body mass index of greater than 45; or an
unability, or unwillingness, to use patient-controlled anal-
gesia (PCA).
Data for the present study were collected as parl of a
prospective research project examining the effects of add-
ing a single dose of GBP to a multimodal anesthetic
regimen with spinal anesthesia [19]. Patients were recruited
aI their preoperative assessment visit approximately
l-2 weeks in advance of their surgery. At that time, the
study procedures were explained to the patients, including
the use of the PCA pump and the visual analogue pain scale
(VAS) (a l0 cm scale with endpoints labeled "no pain"
and "worst pain possible").
The above sample was comprised of 114 patients who
participated in a double-blind, randomized, controlled trial
in which all participants had received acetaminophen I g
p.o. and celecoxib 400 mg p.o. 2 h preoperatively t191.
The focus of the study was to examine the effects of GBP
on anxiety, postoperative pain and opioid consumption.
Patients were randomly assigned to one of three treatment
groups (before/after anesthesia): Group I : placebo/placebo;
Group 2: GBP/?lacebo; Group 3: placebo/GBP. Group 2
received GBP 600 mg p.o. 2 h prior to surgery; the other
groups received a placebo capsule that looked identical to
the GBP capsule. Group 3 received GBP 600 mg p.o. upon
arrival at the postanesthetic care unit; the other groups
received a placebo capsule that looked identical to the GBP
capsule. All patients received an i.v. PCA pain pump and
opioid consumption was recorded for the first 48 h after
surgery. Also, patients were asked to rate their pain
intensity using the VAS described earlier: patient pain
scores at rest and movement-evoked pain scores were
recorded every 4 h up to 48 h after surgery [19].
For the present study, additional approval by the Sun-
nybrook Health Sciences Centre Research Ethics Board
was obtained. Patients were contacted and verbally re-
consented to panicipation by telephone 6 months after
surgery. A maximum of three calls were made and a voice
message was left on the third call. Patients were considered
lost to follow-up if they could not be reached and did not
return the call. Patients were administered the following
three questionnaires: a follow-up Hip Arthroplasty Pain
Questionnaire, The Neuropathic Pain Scale [25], and The
Hospital Anxiety and Depression Scale [26]. Pain intensity
was measured with a numeric rating scale (NRS).The NRS
consists of a series of numbers ranging from 0 to l0 with
endpoints representing the most extreme pain experiences
(0 : no pain, 10 : worst possible pain). The NRS has
been shown to have good reliability and validity and is
sensitive to change following pharmacological intervention
1271.
Statistical analysis
Demographic and clinical variables were compared
between patients with and without pain at 6 months using
the Mann-Whitney U test (for continuous data) and Fish-
er's exact test (for categorical data). A multivariate logistic
regression model predicting the presence or absence of
pain at 6 months from age, treatment group, cumulative
morphine consumption (48 h postoperatively) and maximal
movement-evoked pain intensity over the first 48 h after
surgery was fitted to the data. Thus, the regression model
examined the extent to which acute maximal movement
evoked pain in the first 48 h after surgery predicted the
development of CPSP 6 months later after controlling for
relevant clinical and demographic factors.
Results
recruitment into the trial. Of these, 121 did not meet the
inclusion criteria (34 were older than 75 years of age,29
had diabetes and./or an elevated creatinine, 16 declared an
allergy to one of the study medications, 12 had a history of
being on chronic pain medications, 11 presented with a
psychiatric disorder, t had a BMI >45, 5 were not profi-
cient in English, and 5 had rheumatoid arthritis).
Incidence of chronic pain
One hundred and twenty-six patients were recruited into
the study. One hundred and fourteen patients completed the
in-hospital protocol. Six months after surgery,82 (71.97o;
51 male, 31 female) of the I 14 patients who completed the
study were interviewed. Between the in-hospital interven-
tion and 6-month follow-up, 20 patients were lost to
follow-up (unable to be contacted) and 12 refused to be
interviewed. Of the 82 patients that were interviewed at
6 months, 3l (37.57o) patients reported chronic pain rela-
ted to their hip arthroplasty (i.e. 27Vo of the total number of
patients that completed the in-hospital protocol (3llll4).
Predictors of the development of chronic pain
Table I shows the primary and secondary outcome mea-
sures for patients that reported and did not report pain
6 months after surgery. The results of the data analyses did
not show evidence of a significant association between
the presence or absence of CPSP at 6 months and age
Figure I depicts the recruitment
patients. Overall 439 patients
Fig. 1 Patient recruitment and
patient flow
and retention of study
were screened for
n = 121 Ineligible
n = 192 Declined to participate
N = 3 Required general anesthesia
and removed from study
N = 4 Surgery cancelled zrfter
preoperative medications given
N = 5 Removed due to pro{ocol
violations
N = 20 Patients losr ro follow up
N = 1 2 Patients refused to be
interviewed
N=82
Completed the 6 month
follow up telephone
interview
N= 126
Consent obtained and
randomized
N= 114
Completed in hospital
acute pain component
Table 1 Primary and
secondary outcome measures
shown for patients that reported
and did not report pain
6 months after surgery
Factor Patients with chronic Patients that reported P value
pain 6 months after no pain 6 months post
surgery (n: 3l) surgery (n:51)
Maximal pain intensity with movement
after surgery (VAS 0-100)
Cumulative morphine consumption
at 48 h after surgery
Preoperative anxiety (VAS 0-100)
Age (years)
Gender (M/F)
Group randomization (placebo/pre-/post-)
60.7 + 23.2
49.4 + 26.2
23.3 + 20.3
59.0 + 8.8
r7t14
10n2t9
58.4 + 19.3
469 + 30.3
zJ.I T Zf.l
6t.6 + 9.3
34n'l
t8n6n7
0.38
0.68
0.96
0. l7
0.35
0.85
Covariates of the model predicting
the incidence of chronic postsurgical pain
Beta Standard
EITOT
Chi-square P valueTable 2 Multivariate logistrc
regression model predicting the
development of chronic
postsurgical pain 6 months after
total hip arthroplasty
Likelihood ratio test against
intercept-only model, P 
- 
0.59.
Significance not found with
above model
Intercept
Age
Group randomization: Group I
Group randomization: Group 2
Cumulative morphine consumption
Maximal pain intensity with movemenl
1.43
-0.046
0.1
0.25
-0.002
0.012
1.87
0.027
0.6
0.6
0.009
0.012
0.59
2.77
0.028
0.168
0.06
0.88
0.44
0.1
0.87
0.68
0.81
0.35
(P : 0.17), gender (P : 0.35), group randomization
(P : 0.85), cumulative morphine consumption (P : 0.68),
preoperative anxiety (P : 0.96) or acute maximal move-
ment-evoked pain after surgery (P : 0.38). Using maxi-
mal-evoked pain intensity (P :0.38) as the outcome of
interest, the multivariate logistic regression model using
age (P: 0.09), group randomization (P : 0.91), and
cumulative morphine consumption (P : 0.8) as covariates
also failed to show a significant relationship with the
presence of CPSP after total hip arthroplasty (likelihood
ratio test against the intercept only model P : 0.59)
(Table 2).
Discussion
The results of the present prospective study demonstrate
that 37.5Vo (3I/82) of patients report CPSP 6 months after
total hip arthroplasty. None of the following factors pre-
dicted the development of CPSP 6 months after surgery:
maximal-movement evoked pain intensity after surgery
cumulative morphine consumption at 48 h after surgery,
preoperative anxiety, age, gender, or treatment with GBP
(Table l). Consistent with these findings, the multiple
logistic regression model (Table 2) failed to show a sig-
nificant association between maximal acute pain on
movement and the development of CPSP 6 months after
surgery.
The average daily pain intensity scores at 6 months were
<4/10 (i.e. mild to moderate in magnitude) and were
accompanied by little disruption in daily functioning [9].
Likewise, in the immediate postoperative period (-48 h),
pain at rest and with movement were well managed (mean
<4110) throughout [19]. Given the finding that intense
acute pain predicts the development of CPSP 14,9-121, the
mild to moderate intensity of the maximal movement
evoked pain intensity (Table 1) in the present study may
have contributed to the lack of an association between the
intensity of acute postoperative pain and the long-term
development of CPSP.
The mild to moderate pain experienced postoperatively
is likely due to the aggressive multimodal perioperative
regimen routinely used at our institution [i.e. opioids,
acetaminophen, nonsteroidal anti-infl ammatories (COX-2
inhibitor), and gabapentinoids (a25 calcium channel
blocker)1. Other studies that reported associations between
acute postoperative pain and the development of CPSP
syndromes had cohorts of patients that reported signifi-
cantly higher acute pain scores after limb arthroplasty [28]
and postmastectomy 1221. Katz and colleagues [11] dem-
onstrated an association with moderate to severe acute
postoperative pain and the development of CPSP after
posterolateral thoracotomy. This finding is consistent with
recent results reported by Gottschalk and Ochroch [20].
More data are needed to determine whether similar mul-
timodal pain regimens which tend to be effective in
reducing acute postoperative pain intensity also reduce the
correlation between acute pain intensity and pain
chronicity.
The present study also examined the relationship
between preoperative anxiety scores and the development
of CPSP. Previous studies have demonstrated that high
preoperative anxiety is associated with increased acute
postoperati ve p ain [29], postoperative analgesic consump-
tion 1291, and the development of CPSP [16, 30, 3l]. Our
results failed to demonstrate such an association. The
baseline preoperative anxiety levels were quite low in our
cohort, with mean scores of less than 3/10 preoperatively in
both groups (Table 1). These very low baseline anxiety
scores may have created a floor effect in which clinically
meaningful reductions in anxiety were not possible. Further
examination of the preoperative anxiolytic effects of GBP
should be undertaken using patients with higher preoper-
ative anxiety scores.
Notwithstanding the negative results of the present
study, pain is influenced by a host ofpsychological factors,
and based on the Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials (IMMPACT) consensus
guidelines, it has been recommended that psychological
variables should be examined in pain-related clinical trials
[32]. Psychological variables such as preoperative state
anxiety [16], an introverted personality [33], high catas-
trophizing, greater social support, and solicitous respond-
ing in the week after amputation [34, 35], higher
concurrent emotional numbing scores at 6 and 12 months
[18], greater preoperative catastrophizing [30, 31], feal of
surgery l2ll, and "psychic vulnerability" [36], a construct
similar to neuroticism [37] have all been associated with
the development of CPSP [4]. Further research is needed
with respect to determining the extent to which these risk
factors predict the development of CPSP after total hip
arthroplasty.
Factors such as age [9, 22], female gender 1221, and
opioid consumption have been identified as predictors of
the transition to CPSP [4]. Our results failed to demon-
strate such associations (Table 1). In comparison with
other studies, the mean opioid consumption after THA in
both groups was quite low [38, 39]. It is well established
that the intensity of postoperative pain is correlated with
the amount of opioid medication consumed by the patient
[38]. The relatively infrequent use of opioid analgesics in
our cohort is likely attributable to the adjunctive medi-
cations given, which decreased the pain intensity. Studies
have reported that female gender [9] and younger age
[9, 40) predicted intense acute postoperative pain, and
nationwide surveys consistently find that the incidence of
chronic neuropathic pain is significantly higher in women
than men [4143]. Several smaller studies of CPSP have
also identified younger age as a risk factor for the tran-
sition from acute pain to pain chronicity [14, 22]. The
sample of patients enrolled in the present study was quite
homogeneous with respect to age and gender and neither
predicted chronic pain 6 months after total hip arthro-
plasty [19].
There are several limitations to the present study. First,
preoperative baseline variables were not recorded with
respect to patients' preoperative pain. Previous studies
have demonstrated that one of the most consistent patient-
related predictors of acute and CPSP is preoperative pain
[4, 10, 37]. Furthermore, TlVo (82/ll4) of parients were
reached for follow-up 6 months after surgery, raising the
possibility that our results may have been biased by
patients with chronic pain (i.e., if the remaining 29Vo did
not have pain). However in the event that the entire cohort
had responded, a 27Vo (31/ll4) incidence of chronic pain
would have been higher than expected given the very good
perioperative pain control. The aggressive multimodal
analgesic regimen used in the present study is unique with
respect to the examination of CPSP. When compared to
other postsurgical cohorts used to report the incidence of
CPSP, patients in our study were exposed to various
analgesic agents. Table 1 demonstrates that the maximal
pain intensity typically experienced by our patient cohort
tended to be of a moderate nature, so the heterogeneous
cocktail of medications given to our patients could also be
viewed as a limitation to the current study.
Our results continue to highlight the complexity of
attempting to determine potential risk factors responsible
for the tralsition of acute pain to a CPSP syndrome. The
transition to chronicity is a developmental process that
likely involves biological, psychological, and socioenvi-
ronmental factors [4]. We were unable to identify any such
risk factors associated with this transition. Whether CpSp
develops based on the intensity of acute pain after the
surgical experience, damage to neuronal structures that
leads to long-lasting neuropathic pain, the patient's psy-
chological vulnerabilities, or other factors remains to be
elucidated. It is clear that well-designed trials are needed to
determine the factors that predict the development of
CPSP.
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